2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|March 6, 2015
Mallinckrodt Accents Critical Care With Ikaria Acquisition
Author(s)Pharmaceutical Technology Editors
Mallinckrodt Pharmaceuticals has bought Ikaria, a privately-held critical care company, for $2.3 billion.
Advertisement
Mallinckrodt Pharmaceuticals, a specialty biopharmaceutical company, has inked a deal for $2.3 billion with Ikaria, a privately-held critical care company focused on the development and commercialization of innovative
therapies and delivery systems. The deal is expected to increase Mallinckrodt's net sales by $150 million.
Ikaria's leading product, FDA-approved Inomax, is a vasodilator that is designed for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure, in conjuction with ventilatory support and
other treatments. Inomax improves oxygenation and reduces the need for extracorporeal membrane oxygenation and is specifically indicated for patients experiencing hypoxic respiratory failure associated with clinical
or endocardiographic evidence of pulmonary hypertension, according to a press release.
Source:
Advertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement